Shopping Cart 0
Cart Subtotal
USD 0

Organ Function Assays - Medical Devices Pipeline Assessment, 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Organ Function Assays-Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, Organ Function Assays-Medical Devices Pipeline Assessment, 2018" provides an overview of Organ Function Assays currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Organ Function Assays pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Organ Function Assays under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Organ Function Assays and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry.

Reasons to buy

The report enables you to-

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Organ Function Assays under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date.

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 Introduction 6

2.1 Organ Function Assays Overview 6

3 Products under Development 7

3.1 Organ Function Assays-Pipeline Products by Stage of Development 7

3.2 Organ Function Assays-Pipeline Products by Territory 8

3.3 Organ Function Assays-Pipeline Products by Regulatory Path 9

3.4 Organ Function Assays-Pipeline Products by Estimated Approval Date 10

3.5 Organ Function Assays-Ongoing Clinical Trials 11

4 Organ Function Assays-Pipeline Products under Development by Companies 12

4.1 Organ Function Assays Companies-Pipeline Products by Stage of Development 12

4.2 Organ Function Assays-Pipeline Products by Stage of Development 13

5 Organ Function Assays Companies and Product Overview 14

5.1 Boditech Med Inc Company Overview 14

5.2 CareDx Inc Company Overview 15

5.3 China Medical Technologies Inc (Inactive) Company Overview 16

5.4 Cornell University Company Overview 19

5.5 Daxor Corp Company Overview 20

5.6 EMD Millipore Corp Company Overview 21

5.7 French National Institute of Health and Medical Research Company Overview 22

5.8 HepQuant Llc Company Overview 23

5.9 Humedics GmbH Company Overview 28

5.10 Marx Biotechnology Ltd Company Overview 29

5.11 Myriad Genetics Inc Company Overview 30

5.12 Proteome Sciences Plc Company Overview 31

5.13 Radboud University Nijmegen Medical Centre Company Overview 32

5.14 Research & Diagnostic Antibodies LLC Company Overview 33

5.15 Schnellgen, Inc Company Overview 34

6 Organ Function Assays- Recent Developments 35

6.1 Jun 28, 2018: Flatiron Health CMO/CSO Joins CareDx Board of Directors 35

6.2 Jun 19, 2018: CareDx set to join Russell 2000, Russell 3000 and Russell Microcap Indexes 35

6.3 Jun 12, 2018: Daxor Names Kathryn A. Kornafel As Vice President Of Marketing And Commercial Development 36

6.4 Jun 12, 2018: Change at the top of the Segment Advanced Therapies at Siemens Healthineers 36

6.5 May 10, 2018: CareDx Reports First Quarter Results 37

6.6 May 08, 2018: Myriad Genetics Reports Fiscal Third-Quarter 2018 Financial Results 38

6.7 May 03, 2018: Siemens Healthineers fully on track to meet the targets 39

6.8 May 01, 2018: Maravai LifeSciences Expands Top Management Team with Four New Hires 40

6.9 Apr 24, 2018: Proteome Sciences Appoints Richard Dennis As Board Director 41

6.10 Apr 24, 2018: Proteome Sciences: Preliminary results for the year ended 31 December 2017 41

6.11 Apr 23, 2018: Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Myriad Genetics, Inc. 46

6.12 Mar 22, 2018: CareDx Announces Fourth Quarter And FY2017 Financial Results 46

6.13 Mar 06, 2018: HepQuant Appoints Richard Whitcomb As Chief Operating Officer 48

6.14 Feb 06, 2018: Myriad Genetics Reports Fiscal Second-Quarter 2018 Financial Results 49

6.15 Jan 30, 2018: Siemens Healthineers Names Deepak Nath Head of Laboratory Diagnostics 50

6.16 Jan 25, 2018: HepQuant and CTI Clinical Trial and Consulting Services Announce First Patient Enrolled in Liver Disease Diagnostic Trial 50

6.17 Jan 08, 2018: SeraCare Life Sciences Announces Joe Bernardo as New Company Chairman 51

6.18 Jan 08, 2018: CareDx Reports Preliminary Fourth Quarter and FY2017 Financial Results 52

6.19 Nov 29, 2017: Siemens plans to list Siemens Healthineers on Frankfurt Stock Exchange 52

6.20 Nov 09, 2017: CareDx Reports Third Quarter 2017 Financial Results 53

6.21 Nov 07, 2017: Myriad Genetics Reports Fiscal First-Quarter 2018 Financial Results 54

6.22 Oct 31, 2017: HepQuant Makes Change to Regulatory Team 55

6.23 Oct 18, 2017: Proteome Sciences: GCLP Accreditation and Trading Update 56

6.24 Sep 28, 2017: HepQuant to Sponsor its First Clinical Study 56

6.25 Sep 26, 2017: Aushon BioSystems and ABL Announce Adoption of the Cira Platform for Multiplex and Ultrasensitive Biomarker Testing 57

6.26 Sep 14, 2017: HepQuant Announces Approval of Fourth Investigational Device Exemption Application 57

6.27 Sep 06, 2017: Savyon will Exhibit at the MEDICA (Nov 13-16, 2017) 58

6.28 Aug 16, 2017: ProQinase is now ISO 9001:2015 certified 58

6.29 Aug 10, 2017: CareDx Reports Second Quarter 2017 Financial Results 58

6.30 Aug 01, 2017: Proteome Sciences: Directorate changes 59

6.31 Jul 25, 2017: Proteome Sciences: Interim Results for the Six Months Ended 30 June 2017 60

6.32 Jul 11, 2017: Strategic Collaboration Between Aushon BioSystems and RDL Reference Laboratory Announced for Advancing Precision Medicine 60

7 Appendix 62

7.1 Methodology 62

7.2 About GlobalData 65

7.3 Contact Us 65

7.4 Disclaimer 65


List Of Figure

1.2 List of Figures

Figure 1: Organ Function Assays-Pipeline Products by Stage of Development 7

Figure 2: Organ Function Assays-Pipeline Products by Territory 8

Figure 3: Organ Function Assays-Pipeline Products by Regulatory Path 9

Figure 4: Organ Function Assays-Pipeline Products by Estimated Approval Date 10

Figure 5: Organ Function Assays-Ongoing Clinical Trials 11


List Of Table

1.1 List of Tables

Table 1: Organ Function Assays-Pipeline Products by Stage of Development 7

Table 2: Organ Function Assays-Pipeline Products by Territory 8

Table 3: Organ Function Assays-Pipeline Products by Regulatory Path 9

Table 4: Organ Function Assays-Pipeline Products by Estimated Approval Date 10

Table 5: Organ Function Assays-Ongoing Clinical Trials 11

Table 6: Organ Function Assays Companies-Pipeline Products by Stage of Development 12

Table 7: Organ Function Assays-Pipeline Products by Stage of Development 13

Table 8: Boditech Med Inc Pipeline Products & Ongoing Clinical Trials Overview 14

Table 9: AFIAS-6-Cystatin C Test-Product Status 14

Table 10: AFIAS-6-Cystatin C Test-Product Description 14

Table 11: CareDx Inc Pipeline Products & Ongoing Clinical Trials Overview 15

Table 12: Post Transplant Management-Lung Transplant-Product Status 15

Table 13: Post Transplant Management-Lung Transplant-Product Description 15

Table 14: China Medical Technologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 16

Table 15: Diagnostic Assay-Alpha 1-Microglobulin-Product Status 16

Table 16: Diagnostic Assay-Alpha 1-Microglobulin-Product Description 16

Table 17: Diagnostic Assay-2-Microglobulin-Product Status 17

Table 18: Diagnostic Assay-2-Microglobulin-Product Description 17

Table 19: Diagnostic Assay-Urea Albumin-Product Status 17

Table 20: Diagnostic Assay-Urea Albumin-Product Description 18

Table 21: Cornell University Pipeline Products & Ongoing Clinical Trials Overview 19

Table 22: Diagnostic Test-Kidney Allograft Dysfunction-Product Status 19

Table 23: Diagnostic Test-Kidney Allograft Dysfunction-Product Description 19

Table 24: Daxor Corp Pipeline Products & Ongoing Clinical Trials Overview 20

Table 25: BVA-100 Glomerular Filtration Rate-Product Status 20

Table 26: BVA-100 Glomerular Filtration Rate-Product Description 20

Table 27: EMD Millipore Corp Pipeline Products & Ongoing Clinical Trials Overview 21

Table 28: Kidney Toxicity Biomarker Test-Product Status 21

Table 29: Kidney Toxicity Biomarker Test-Product Description 21

Table 30: French National Institute of Health and Medical Research Pipeline Products & Ongoing Clinical Trials Overview 22

Table 31: Kidney Transplant Rejection Assay-Product Status 22

Table 32: Kidney Transplant Rejection Assay-Product Description 22

Table 33: HepQuant Llc Pipeline Products & Ongoing Clinical Trials Overview 23

Table 34: HepQuant-Dual-Product Status 23

Table 35: HepQuant-Dual-Product Description 23

Table 36: HepQuant-FLOW-Product Status 24

Table 37: HepQuant-FLOW-Product Description 24

Table 38: HepQuant-SHUNT-Product Status 24

Table 39: HepQuant-SHUNT-Product Description 25

Table 40: HepQuant-STAT-Product Status 25

Table 41: HepQuant-STAT-Product Description 25

Table 42: HepQuant Llc-Ongoing Clinical Trials Overview 26

Table 43: HepQuant-SHUNT-Intra-individual Reproducibility of the Non-invasive Assessment of the Portal Circulation 27

Table 44: HepQuant-SHUNT-The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology 27

Table 45: Humedics GmbH Pipeline Products & Ongoing Clinical Trials Overview 28

Table 46: LiMAx Test-Product Status 28

Table 47: LiMAx Test-Product Description 28

Table 48: Marx Biotechnology Ltd Pipeline Products & Ongoing Clinical Trials Overview 29

Table 49: Blood Test-Graft Versus Host Disease (GVHD)-Product Status 29

Table 50: Blood Test-Graft Versus Host Disease (GVHD)-Product Description 29

Table 51: Myriad Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview 30

Table 52: Diagnostic Test-Kidney Damage-Product Status 30

Table 53: Diagnostic Test-Kidney Damage-Product Description 30

Table 54: Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 31

Table 55: Biomarker Test-Acute Liver Failure-Product Status 31

Table 56: Biomarker Test-Acute Liver Failure-Product Description 31

Table 57: Radboud University Nijmegen Medical Centre Pipeline Products & Ongoing Clinical Trials Overview 32

Table 58: Renal Toxicity Screening Assay-Product Status 32

Table 59: Renal Toxicity Screening Assay-Product Description 32

Table 60: Research & Diagnostic Antibodies LLC Pipeline Products & Ongoing Clinical Trials Overview 33

Table 61: Diagnostic Test-Transplant And Graft Rejection-Product Status 33

Table 62: Diagnostic Test-Transplant And Graft Rejection-Product Description 33

Table 63: Schnellgen, Inc Pipeline Products & Ongoing Clinical Trials Overview 34

Table 64: Quantitative High-throughput Assay-Nephrotoxicity-Product Status 34

Table 65: Quantitative High-throughput Assay-Nephrotoxicity-Product Description 34

Table 66: Glossary 64

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Boditech Med Inc, AFIAS-6 - Cystatin C Test; CareDx Inc, Post Transplant Management-Lung Transplant; China Medical Technologies Inc (Inactive), Diagnostic Assay - Alpha 1-Microglobulin; China Medical Technologies Inc (Inactive), Diagnostic Assay - 2-Microglobulin; China Medical Technologies Inc (Inactive), Diagnostic Assay - Urea Albumin; Cornell University, Diagnostic Test - Kidney Allograft Dysfunction; Daxor Corp, BVA-100 Glomerular Filtration Rate; EMD Millipore Corp, Kidney Toxicity Biomarker Test; French National Institute of Health and Medical Research, Kidney Transplant Rejection Assay; HepQuant Llc, HepQuant-Dual; HepQuant Llc, HepQuant-FLOW; HepQuant Llc, HepQuant-SHUNT; HepQuant Llc, HepQuant-STAT; Humedics GmbH, LiMAx Test; Marx Biotechnology Ltd, Blood Test - Graft Versus Host Disease (GVHD); Myriad Genetics Inc, Diagnostic Test - Kidney Damage; Proteome Sciences Plc, Biomarker Test - Acute Liver Failure; Radboud University Nijmegen Medical Centre, Renal Toxicity Screening Assay; Research &; Diagnostic Antibodies LLC, Diagnostic Test - Transplant And Graft Rejection; Schnellgen, Inc, Quantitative High-throughput Assay - Nephrotoxicity


Companies

Boditech Med Inc

CareDx Inc

China Medical Technologies Inc

Cornell University

Daxor Corp

EMD Millipore Corp

French National Institute of Health and Medical Research

HepQuant Llc

Humedics GmbH

Marx Biotechnology Ltd

Myriad Genetics Inc

Proteome Sciences Plc

Radboud University Nijmegen Medical Centre

Research & Diagnostic Antibodies LLC

Schnellgen, Inc

Organ Function Assays-Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, Organ Function Assays-Medical Devices Pipeline Assessment, 2018" provides an overview of Organ Function Assays currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Organ Function Assays pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Organ Function Assays under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Organ Function Assays and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry.

Reasons to buy

The report enables you to-

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Organ Function Assays under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date.

READ MORE

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 Introduction 6

2.1 Organ Function Assays Overview 6

3 Products under Development 7

3.1 Organ Function Assays-Pipeline Products by Stage of Development 7

3.2 Organ Function Assays-Pipeline Products by Territory 8

3.3 Organ Function Assays-Pipeline Products by Regulatory Path 9

3.4 Organ Function Assays-Pipeline Products by Estimated Approval Date 10

3.5 Organ Function Assays-Ongoing Clinical Trials 11

4 Organ Function Assays-Pipeline Products under Development by Companies 12

4.1 Organ Function Assays Companies-Pipeline Products by Stage of Development 12

4.2 Organ Function Assays-Pipeline Products by Stage of Development 13

5 Organ Function Assays Companies and Product Overview 14

5.1 Boditech Med Inc Company Overview 14

5.2 CareDx Inc Company Overview 15

5.3 China Medical Technologies Inc (Inactive) Company Overview 16

5.4 Cornell University Company Overview 19

5.5 Daxor Corp Company Overview 20

5.6 EMD Millipore Corp Company Overview 21

5.7 French National Institute of Health and Medical Research Company Overview 22

5.8 HepQuant Llc Company Overview 23

5.9 Humedics GmbH Company Overview 28

5.10 Marx Biotechnology Ltd Company Overview 29

5.11 Myriad Genetics Inc Company Overview 30

5.12 Proteome Sciences Plc Company Overview 31

5.13 Radboud University Nijmegen Medical Centre Company Overview 32

5.14 Research & Diagnostic Antibodies LLC Company Overview 33

5.15 Schnellgen, Inc Company Overview 34

6 Organ Function Assays- Recent Developments 35

6.1 Jun 28, 2018: Flatiron Health CMO/CSO Joins CareDx Board of Directors 35

6.2 Jun 19, 2018: CareDx set to join Russell 2000, Russell 3000 and Russell Microcap Indexes 35

6.3 Jun 12, 2018: Daxor Names Kathryn A. Kornafel As Vice President Of Marketing And Commercial Development 36

6.4 Jun 12, 2018: Change at the top of the Segment Advanced Therapies at Siemens Healthineers 36

6.5 May 10, 2018: CareDx Reports First Quarter Results 37

6.6 May 08, 2018: Myriad Genetics Reports Fiscal Third-Quarter 2018 Financial Results 38

6.7 May 03, 2018: Siemens Healthineers fully on track to meet the targets 39

6.8 May 01, 2018: Maravai LifeSciences Expands Top Management Team with Four New Hires 40

6.9 Apr 24, 2018: Proteome Sciences Appoints Richard Dennis As Board Director 41

6.10 Apr 24, 2018: Proteome Sciences: Preliminary results for the year ended 31 December 2017 41

6.11 Apr 23, 2018: Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Myriad Genetics, Inc. 46

6.12 Mar 22, 2018: CareDx Announces Fourth Quarter And FY2017 Financial Results 46

6.13 Mar 06, 2018: HepQuant Appoints Richard Whitcomb As Chief Operating Officer 48

6.14 Feb 06, 2018: Myriad Genetics Reports Fiscal Second-Quarter 2018 Financial Results 49

6.15 Jan 30, 2018: Siemens Healthineers Names Deepak Nath Head of Laboratory Diagnostics 50

6.16 Jan 25, 2018: HepQuant and CTI Clinical Trial and Consulting Services Announce First Patient Enrolled in Liver Disease Diagnostic Trial 50

6.17 Jan 08, 2018: SeraCare Life Sciences Announces Joe Bernardo as New Company Chairman 51

6.18 Jan 08, 2018: CareDx Reports Preliminary Fourth Quarter and FY2017 Financial Results 52

6.19 Nov 29, 2017: Siemens plans to list Siemens Healthineers on Frankfurt Stock Exchange 52

6.20 Nov 09, 2017: CareDx Reports Third Quarter 2017 Financial Results 53

6.21 Nov 07, 2017: Myriad Genetics Reports Fiscal First-Quarter 2018 Financial Results 54

6.22 Oct 31, 2017: HepQuant Makes Change to Regulatory Team 55

6.23 Oct 18, 2017: Proteome Sciences: GCLP Accreditation and Trading Update 56

6.24 Sep 28, 2017: HepQuant to Sponsor its First Clinical Study 56

6.25 Sep 26, 2017: Aushon BioSystems and ABL Announce Adoption of the Cira Platform for Multiplex and Ultrasensitive Biomarker Testing 57

6.26 Sep 14, 2017: HepQuant Announces Approval of Fourth Investigational Device Exemption Application 57

6.27 Sep 06, 2017: Savyon will Exhibit at the MEDICA (Nov 13-16, 2017) 58

6.28 Aug 16, 2017: ProQinase is now ISO 9001:2015 certified 58

6.29 Aug 10, 2017: CareDx Reports Second Quarter 2017 Financial Results 58

6.30 Aug 01, 2017: Proteome Sciences: Directorate changes 59

6.31 Jul 25, 2017: Proteome Sciences: Interim Results for the Six Months Ended 30 June 2017 60

6.32 Jul 11, 2017: Strategic Collaboration Between Aushon BioSystems and RDL Reference Laboratory Announced for Advancing Precision Medicine 60

7 Appendix 62

7.1 Methodology 62

7.2 About GlobalData 65

7.3 Contact Us 65

7.4 Disclaimer 65


List Of Figure

1.2 List of Figures

Figure 1: Organ Function Assays-Pipeline Products by Stage of Development 7

Figure 2: Organ Function Assays-Pipeline Products by Territory 8

Figure 3: Organ Function Assays-Pipeline Products by Regulatory Path 9

Figure 4: Organ Function Assays-Pipeline Products by Estimated Approval Date 10

Figure 5: Organ Function Assays-Ongoing Clinical Trials 11


List Of Table

1.1 List of Tables

Table 1: Organ Function Assays-Pipeline Products by Stage of Development 7

Table 2: Organ Function Assays-Pipeline Products by Territory 8

Table 3: Organ Function Assays-Pipeline Products by Regulatory Path 9

Table 4: Organ Function Assays-Pipeline Products by Estimated Approval Date 10

Table 5: Organ Function Assays-Ongoing Clinical Trials 11

Table 6: Organ Function Assays Companies-Pipeline Products by Stage of Development 12

Table 7: Organ Function Assays-Pipeline Products by Stage of Development 13

Table 8: Boditech Med Inc Pipeline Products & Ongoing Clinical Trials Overview 14

Table 9: AFIAS-6-Cystatin C Test-Product Status 14

Table 10: AFIAS-6-Cystatin C Test-Product Description 14

Table 11: CareDx Inc Pipeline Products & Ongoing Clinical Trials Overview 15

Table 12: Post Transplant Management-Lung Transplant-Product Status 15

Table 13: Post Transplant Management-Lung Transplant-Product Description 15

Table 14: China Medical Technologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 16

Table 15: Diagnostic Assay-Alpha 1-Microglobulin-Product Status 16

Table 16: Diagnostic Assay-Alpha 1-Microglobulin-Product Description 16

Table 17: Diagnostic Assay-2-Microglobulin-Product Status 17

Table 18: Diagnostic Assay-2-Microglobulin-Product Description 17

Table 19: Diagnostic Assay-Urea Albumin-Product Status 17

Table 20: Diagnostic Assay-Urea Albumin-Product Description 18

Table 21: Cornell University Pipeline Products & Ongoing Clinical Trials Overview 19

Table 22: Diagnostic Test-Kidney Allograft Dysfunction-Product Status 19

Table 23: Diagnostic Test-Kidney Allograft Dysfunction-Product Description 19

Table 24: Daxor Corp Pipeline Products & Ongoing Clinical Trials Overview 20

Table 25: BVA-100 Glomerular Filtration Rate-Product Status 20

Table 26: BVA-100 Glomerular Filtration Rate-Product Description 20

Table 27: EMD Millipore Corp Pipeline Products & Ongoing Clinical Trials Overview 21

Table 28: Kidney Toxicity Biomarker Test-Product Status 21

Table 29: Kidney Toxicity Biomarker Test-Product Description 21

Table 30: French National Institute of Health and Medical Research Pipeline Products & Ongoing Clinical Trials Overview 22

Table 31: Kidney Transplant Rejection Assay-Product Status 22

Table 32: Kidney Transplant Rejection Assay-Product Description 22

Table 33: HepQuant Llc Pipeline Products & Ongoing Clinical Trials Overview 23

Table 34: HepQuant-Dual-Product Status 23

Table 35: HepQuant-Dual-Product Description 23

Table 36: HepQuant-FLOW-Product Status 24

Table 37: HepQuant-FLOW-Product Description 24

Table 38: HepQuant-SHUNT-Product Status 24

Table 39: HepQuant-SHUNT-Product Description 25

Table 40: HepQuant-STAT-Product Status 25

Table 41: HepQuant-STAT-Product Description 25

Table 42: HepQuant Llc-Ongoing Clinical Trials Overview 26

Table 43: HepQuant-SHUNT-Intra-individual Reproducibility of the Non-invasive Assessment of the Portal Circulation 27

Table 44: HepQuant-SHUNT-The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology 27

Table 45: Humedics GmbH Pipeline Products & Ongoing Clinical Trials Overview 28

Table 46: LiMAx Test-Product Status 28

Table 47: LiMAx Test-Product Description 28

Table 48: Marx Biotechnology Ltd Pipeline Products & Ongoing Clinical Trials Overview 29

Table 49: Blood Test-Graft Versus Host Disease (GVHD)-Product Status 29

Table 50: Blood Test-Graft Versus Host Disease (GVHD)-Product Description 29

Table 51: Myriad Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview 30

Table 52: Diagnostic Test-Kidney Damage-Product Status 30

Table 53: Diagnostic Test-Kidney Damage-Product Description 30

Table 54: Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 31

Table 55: Biomarker Test-Acute Liver Failure-Product Status 31

Table 56: Biomarker Test-Acute Liver Failure-Product Description 31

Table 57: Radboud University Nijmegen Medical Centre Pipeline Products & Ongoing Clinical Trials Overview 32

Table 58: Renal Toxicity Screening Assay-Product Status 32

Table 59: Renal Toxicity Screening Assay-Product Description 32

Table 60: Research & Diagnostic Antibodies LLC Pipeline Products & Ongoing Clinical Trials Overview 33

Table 61: Diagnostic Test-Transplant And Graft Rejection-Product Status 33

Table 62: Diagnostic Test-Transplant And Graft Rejection-Product Description 33

Table 63: Schnellgen, Inc Pipeline Products & Ongoing Clinical Trials Overview 34

Table 64: Quantitative High-throughput Assay-Nephrotoxicity-Product Status 34

Table 65: Quantitative High-throughput Assay-Nephrotoxicity-Product Description 34

Table 66: Glossary 64

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Boditech Med Inc, AFIAS-6 - Cystatin C Test; CareDx Inc, Post Transplant Management-Lung Transplant; China Medical Technologies Inc (Inactive), Diagnostic Assay - Alpha 1-Microglobulin; China Medical Technologies Inc (Inactive), Diagnostic Assay - 2-Microglobulin; China Medical Technologies Inc (Inactive), Diagnostic Assay - Urea Albumin; Cornell University, Diagnostic Test - Kidney Allograft Dysfunction; Daxor Corp, BVA-100 Glomerular Filtration Rate; EMD Millipore Corp, Kidney Toxicity Biomarker Test; French National Institute of Health and Medical Research, Kidney Transplant Rejection Assay; HepQuant Llc, HepQuant-Dual; HepQuant Llc, HepQuant-FLOW; HepQuant Llc, HepQuant-SHUNT; HepQuant Llc, HepQuant-STAT; Humedics GmbH, LiMAx Test; Marx Biotechnology Ltd, Blood Test - Graft Versus Host Disease (GVHD); Myriad Genetics Inc, Diagnostic Test - Kidney Damage; Proteome Sciences Plc, Biomarker Test - Acute Liver Failure; Radboud University Nijmegen Medical Centre, Renal Toxicity Screening Assay; Research &; Diagnostic Antibodies LLC, Diagnostic Test - Transplant And Graft Rejection; Schnellgen, Inc, Quantitative High-throughput Assay - Nephrotoxicity


Companies

Boditech Med Inc

CareDx Inc

China Medical Technologies Inc

Cornell University

Daxor Corp

EMD Millipore Corp

French National Institute of Health and Medical Research

HepQuant Llc

Humedics GmbH

Marx Biotechnology Ltd

Myriad Genetics Inc

Proteome Sciences Plc

Radboud University Nijmegen Medical Centre

Research & Diagnostic Antibodies LLC

Schnellgen, Inc